CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients
1 Rheumatology Unit, Department of Medicine at Karolinska University Hospital, Karolinska Institute, Solna, Stockholm, Sweden
2 Unit for Clinical Therapy Research, Inflammatory Diseases, Karolinska Institute, Solna, Stockholm, Sweden
BMC Immunology 2013, 14:34 doi:10.1186/1471-2172-14-34Published: 5 August 2013
Additional file 1: Figure S1:
Treg frequency is diminished. PBMCs from baseline, 3 months and 6 months following treatment (n=4) were obtained and multicolor flow cytometry was performed. A general reduction in frequency of several Treg associated markers could be seen (A-F). (A) The graph displays CD4+FOXP3+ Treg, (B) Helios+ T cells, (C) CD4+CD39+ T cells, (D) CD45RA+FOXP3+ Treg, (E) CTLA4+ FOXP3+Treg, and (F) CD39+FOXP3+ Treg.
Format: PDF Size: 30KB Download file
This file can be viewed with: Adobe Acrobat Reader